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Abstract
©2016  AACR.Purpose:  Even  when  diagnosed  prior  to  metastasis,  pancreatic  ductal
adenocarcinoma (PDAC) is a devastating malignancy with almost 90% lethality, emphasizing the
need for  new therapies optimally targeting the tumors of  individual  patients.  Experimental
Design: We first developed a panel of new physiologic models for study of PDAC, expanding
surgical PDAC tumor samples in culture using short-term culture and conditional reprogramming
with the Rho kinase inhibitor Y-27632, and creating matched patient-derived xenografts (PDX).
These were evaluated for sensitivity to a large panel of clinical agents, and promising leads
further evaluated mechanistically. Results: Only a small minority of tested agents was cytotoxic
in  minimally  passaged PDAC cultures  in  vitro.  Drugs interfering with  protein  turnover  and
transcription  were  among  most  cytotoxic.  Among  transcriptional  repressors,  triptolide,  a
covalent  inhibitor  of  ERCC3,  was  most  consistently  effective  in  vitro  and  in  vivo  causing
prolonged complete regression in multiple PDX models resistant to standard PDAC therapies.
Importantly, triptolide showed superior activity in MYC-amplified PDX models and elicited rapid
and profound depletion of the oncoprotein MYC, a transcriptional regulator. Expression of ERCC3
and MYC was interdependent in PDACs, and acquired resistance to triptolide depended on
elevated ERCC3 and MYC expression.  The Cancer  Genome Atlas  analysis  indicates  ERCC3
expression predicts poor prognosis,  particularly in CDKN2A-null,  highly proliferative tumors.
Conclusions:  This  provides  initial  preclinical  evidence  for  an  essential  role  of  MYC-ERCC3
interactions in PDAC, and suggests a new mechanistic approach for disruption of critical survival
signaling in MYC-dependent cancers.
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